Xu2018: Safety of Immune Checkpoint Inhibitors in Cancer

In poth: Precision of Treatment Hierarchy (POTH)

Safety of Immune Checkpoint Inhibitors in Cancer

Description

Data from a network meta-analysis on immune checkpoint inhibitors (ICIs) to assess the safety of ICI drugs as cancer treatment (Xu et al., 2018).

Format

A data frame with the following columns:

studyID	study id
treatment	treatment name
adverse	number of adverse events
n	group sample size

Details

Data were obtained from Rosenberger et al. (2021), who re-analysed the data. There are seven treatments and 23 studies. The outcome of interest is the number of treatment-related adverse events, so smaller values indicate a safer treatment.

Source

Rosenberger, K.J., Duan, R., Chen, Y. et al. (2021): Predictive P-score for treatment ranking in Bayesian network meta-analysis. BMC Med Res Methodol 21, 213. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1186/s12874-021-01397-5")}

See Also

netmeta

Examples

data(Xu2018)
head(Xu2018)

library("netmeta")
pw <- pairwise(treat = treatment, event = adverse, n = n,
  studlab = studyID, data = Xu2018, sm = "OR")
#
net <- netmeta(pw, small.values = "desirable", method.tau = "REML",
  common = FALSE)
#
poth(net)

poth documentation built on June 8, 2025, 11:54 a.m.